Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials

Journal of Clinical Oncology

Volumn 32, Issue 6, 2014, Pages 519-526

  Hyman, David M ^a,b   Eaton, Anne A ^a   Gounder, Mrinal M ^a,b   Smith, Gary L ^c   Pamer, Erika G ^a   Hensley, Martee L ^a,b   Spriggs, David R ^a,b   Ivy, Percy ^c   Iasonos, Alexia ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMYLASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYTOTOXIC AGENT; LACTATE DEHYDROGENASE; MOLECULARLY TARGETED AGENT; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOXICITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NOMOGRAM; PHASE 1 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SERIOUS DRUG RELATED TOXICITY; SKIN MANIFESTATION; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VOMITING; ADOLESCENT; COHORT ANALYSIS; FACTUAL DATABASE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; STATISTICS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; COHORT STUDIES; DATABASES, FACTUAL; HUMANS; MIDDLE AGED; NOMOGRAMS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898545465     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.8808     Document Type: Article

References (21)

1. Ho J, Pond GR, Newman C, et al: Barriers in phase I cancer clinical trials referrals and enrollment: Five-year experience at the Princess Margaret Hospital. BMC Cancer 6:263, 2006
2. Karavasilis V, Digue L, Arkenau T, et al: Identification of factors limiting patient recruitment into phase I trials: A study from the Royal Marsden Hospital. Eur J Cancer 44:978-982, 2008
3. Olmos D, A'Hern RP, Marsoni S, et al: Patient selection for oncology phase I trials: A multi-institutional study of prognostic factors. J Clin Oncol 30:996-1004, 2012
4. Arkenau HT, Olmos D, Ang JE, et al: 90-days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial? Eur J Cancer 44:1536-1540, 2008
5. Arkenau HT, Barriuso J, Olmos D, et al: Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 27:2692-2696, 2009
6. Garrido-Laguna I, Janku F, Vaklavas C, et al: Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer 118:1422-1428, 2012
7. Ploquin A, Olmos D, Lacombe D, et al: Prediction of early death among patients enrolled in phase I trials: Development and validation of a new model based on platelet count and albumin. Br J Cancer 107:1025-1030, 2012
8. Molife LR, Alam S, Olmos D, et al: Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single centre experience. Ann Oncol 23:1968-1973, 2012
9. Wheler JJ, Tsimberidou AM, Hong DS, et al: Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: The M. D. Anderson Cancer Center experience. Ann Oncol 23:1963-1967, 2012
10. Ansher SS, Scharf R: The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: Industry collaborations in new agent development. Ann N Y Acad Sci 949:333-340, 2001 (Pubitemid 34059998)
11. Theradex Systems: NCI-CTMS: Partners since 1982. http://www.theradex.com/ CTMS/Default.aspx
12. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) v.4 2010. http://evs.nci.nih.gov/ftp1/CTCAE/About.html
13. National Cancer Institute: Cancer Therapy Evaluation Program: CTC/CTCAE mapping documents. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm#ctc-mapping-docs
14. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996 (Pubitemid 26072233)
15. International Agency for Research on Cancer: Statistical Methods in Cancer Research. Lyon, France, International Agency for Research on Cancer, 1980
16. Iasonos A, Schrag D, Raj GV, et al: How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26:1364-1370, 2008
17. Harrell FE: Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY, Springer, 2001
18. Memorial Sloan-Kettering Cancer Center: Prediction tools. http://www.mskcc.org/cancer-care/prediction-tools
19. Ivy SP, Siu LL, Garrett-Mayer E, et al: Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: A report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res 16:1726-1736, 2010
20. Forster MD, Saijo N, Seymour L, et al: Performing phase I clinical trials of anticancer agents: Perspectives from within the European Union and Japan. Clin Cancer Res 16:1737-1744, 2010
21. Ploquin A, Olmos D, Ferté C, et al: Life-expectancy of patients enrolled in phase 1 clinical trials: A systematic review of published prognostic models. Crit Rev Oncol Hematol 83:242-248, 2012